Furthermore, CDKN2A displayed higher mutation frequency in head and neck squamous cell carcinoma (104%), lung squamous cell carcinoma (73%), skin cutaneous melanoma (61%), pancreatic adenocarcinoma (36%), bladder urothelial carcinoma (27%), and lung adenocarcinoma (24%). This evidence concerns the gene CDKN2A and cutaneous melanoma.